- 全部删除
您的购物车当前为空
Gefitinib-based PROTAC 3 通过 linker 将 EGFR 结合元件与 von Hippel-Lindau 配体结合,在 HCC827(外显子 19 del)和 H3255(L858R 突变)细胞中诱导 EGFR 降解,DC50 分别为 11.7 和 22.3 nM。


为众多的药物研发团队赋能,
让新药发现更简单!
Gefitinib-based PROTAC 3 通过 linker 将 EGFR 结合元件与 von Hippel-Lindau 配体结合,在 HCC827(外显子 19 del)和 H3255(L858R 突变)细胞中诱导 EGFR 降解,DC50 分别为 11.7 和 22.3 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 237 | In stock | |
| 5 mg | ¥ 585 | In stock | |
| 10 mg | ¥ 996 | In stock | |
| 25 mg | ¥ 1,670 | In stock | |
| 50 mg | ¥ 2,380 | In stock | |
| 100 mg | ¥ 3,490 | In stock | |
| 200 mg | ¥ 4,850 | In stock |
Gefitinib-based PROTAC 3 相关产品
| 产品描述 | Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively[1]. |
| 靶点活性 | EGFR:11.7 nM (DC50, HCC827(exon 19 del) cells), EGFR:22.3 nM (DC50, H3255 (L858R mutantion) cells) |
| 体外活性 | H3255细胞表达L858R EGFR,在Gefitinib-based PROTAC 3 (25 nM-10 μM; 24小时)处理下,以及HCC827细胞表达外显子19缺失EGFR,在Gefitinib-based PROTAC 3 (100 nM-10 μM; 24小时)处理下,可实现对包含L858R激活点突变的突变异构体以及外显子19缺失EGFR的降解,同时不影响WT EGFR[1]。 |
| 分子量 | 934.51 |
| 分子式 | C47H57ClFN7O8S |
| CAS No. | 2230821-27-7 |
| Smiles | N(C=1C2=C(C=C(OC)C(OCCCCCOCCOCCC(N[C@H](C(=O)N3[C@H](C(NCC4=CC=C(C=C4)C=5SC=NC5C)=O)C[C@@H](O)C3)[C@](C)(C)C)=O)=C2)N=CN1)C6=CC(Cl)=C(F)C=C6 |
| 密度 | 1.300 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| 溶解度信息 | DMSO: 10 mM, Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
评论内容